Sun Pharmaceutical Industries, India's largest drugmaker, announced it will acquire New Jersey-based Organon & Co in an all-cash transaction valued at $11.75 billion, including debt [1]. Under the terms of the deal, Sun Pharma will purchase all outstanding shares of Organon for $14.00 per share [1]. This acquisition is set to boost Sun Pharma's revenues to $12.4 billion, positioning the company among the top 25 global pharmaceutical firms [1].
Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars, offering more than 70 products across 140 countries [1]. Organon's key markets include the U.S., Europe, China, Canada, and Brazil, supported by six manufacturing facilities in the European Union and emerging markets [1]. Carrie Cox, executive chair at Organon, stated that the all-cash transaction offers 'compelling and immediate value to Organon stockholders' following a comprehensive review of strategic alternatives [1].
Sun Pharma's management emphasized that the acquisition is a strategic move to strengthen its global business and scale its medicine products, particularly in the U.S. market [1]. The deal aligns with Sun Pharma's strategy to grow its Innovative Medicines business, which currently covers dermatology, ophthalmology, and onco-dermatology [1]. In the financial year ending March 2025, Sun Pharma's innovative medicine segment accounted for 20% of total sales, but with the Organon acquisition, this segment is expected to contribute 27% to the company's topline [1].
Market reaction was notable: Organon shares surged nearly 31% on Friday after reports of the potential deal, while Sun Pharma's stock closed 3.6% lower [1].
CONCLUSION
Sun Pharma's $11.75 billion acquisition of Organon marks a significant expansion of its global footprint and product portfolio, particularly in innovative medicines. The deal is expected to enhance Sun Pharma's revenue and market position, though initial market reactions were mixed, with Organon shares rising sharply and Sun Pharma's stock declining. The transaction underscores Sun Pharma's commitment to scaling its presence in key international markets.